TXG – 10x Genomics, Inc.

TXG — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

10.74

Margin Of Safety %

-10

Put/Call OI Ratio

0.41

EPS Next Q Diff

0.12

EPS Last/This Y

0.41

EPS This/Next Y

0.02

Price

59.09

Target Price

68.14

Analyst Recom

2.53

Performance Q

5.37

Upside

-111.4%

Beta

2.03

Ticker: TXG

23 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-13	TXG	71.77	0.45	0.23	24439
2026-10-14	TXG	73.14	0.45	0.13	24597
2026-10-15	TXG	72.38	0.42	0.65	24780
2026-10-16	TXG	69.87	0.40	1.06	24472
2026-10-19	TXG	69.84	0.59	0.27	13995
2026-10-20	TXG	71.4	0.59	0.42	14261
2026-10-21	TXG	75.5	0.58	0.77	14506
2026-10-22	TXG	69.73	0.58	0.23	14601
2026-10-23	TXG	71.47	0.55	0.41	15448
2026-10-26	TXG	72.97	0.54	0.28	15480
2026-10-27	TXG	78.01	0.54	0.35	15514
2026-10-28	TXG	83.63	0.54	0.05	15585
2026-10-29	TXG	81.57	0.46	0.35	17151
2026-10-30	TXG	70.11	0.45	0.09	17438
2026-11-02	TXG	61.6	0.45	0.62	18285
2026-11-03	TXG	65.31	0.44	0.16	18712
2026-11-04	TXG	67.47	0.43	0.07	19177
2026-11-05	TXG	57.93	0.42	0.88	19594
2026-11-06	TXG	59.18	0.43	0.46	20044
2026-11-09	TXG	65.13	0.43	0.44	20007
2026-11-10	TXG	62.88	0.43	0.75	20213
2026-11-11	TXG	62.45	0.43	0.46	20204
2026-11-12	TXG	59.08	0.41	0.34	20046
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

23 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-13	TXG	71.69	12.3	-	0.04
2026-10-14	TXG	73.13	12.3	-	0.04
2026-10-15	TXG	72.38	12.3	-	0.04
2026-10-16	TXG	69.87	12.3	-	0.04
2026-10-19	TXG	69.86	12.3	-	0.04
2026-10-20	TXG	69.86	12.3	-	0.04
2026-10-21	TXG	71.43	12.3	-	0.04
2026-10-22	TXG	69.70	12.3	-	0.04
2026-10-23	TXG	71.44	12.3	-	0.04
2026-10-26	TXG	72.98	12.3	-	0.04
2026-10-27	TXG	78.01	12.3	-	0.04
2026-10-28	TXG	83.58	12.3	-	0.04
2026-10-29	TXG	81.56	12.3	-	0.04
2026-10-30	TXG	70.11	12.3	-	0.04
2026-11-02	TXG	61.60	12.3	-	0.04
2026-11-04	TXG	67.49	12.3	-	0.04
2026-11-05	TXG	57.97	12.3	-	0.04
2026-11-06	TXG	59.32	12.3	-	0.04
2026-11-09	TXG	65.07	-100.0	-	0.04
2026-11-10	TXG	62.88	-100.0	-	0.06
2026-11-11	TXG	62.02	-100.0	-	0.06
2026-11-12	TXG	59.09	-100.0	-	0.06
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-13	TXG	-1.96	7.73	13.23
2026-10-14	TXG	-1.96	7.73	13.23
2026-10-15	TXG	-1.96	7.73	13.23
2026-10-16	TXG	-1.96	7.73	13.23
2026-10-19	TXG	-1.93	5.73	13.23
2026-10-20	TXG	-1.93	5.73	13.23
2026-10-21	TXG	-1.93	5.73	13.23
2026-10-22	TXG	-1.93	5.73	13.23
2026-10-23	TXG	-1.93	5.73	13.23
2026-10-26	TXG	-1.93	5.83	13.23
2026-10-27	TXG	-1.93	5.83	10.96
2026-10-28	TXG	-1.93	5.83	10.96
2026-10-29	TXG	-1.93	5.83	10.96
2026-10-30	TXG	-1.93	5.83	10.96
2026-11-02	TXG	-1.93	5.49	10.96
2026-11-03	TXG	-1.93	5.49	10.96
2026-11-05	TXG	-1.93	5.49	10.96
2026-11-06	TXG	-1.93	5.49	10.96
2026-11-09	TXG	-1.93	5.09	10.96
2026-11-10	TXG	-1.93	5.09	10.96
2026-11-11	TXG	-1.93	5.09	10.74
2026-11-12	TXG	-1.93	5.09	10.74
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.15

Avg. EPS Est. Current Quarter

-0.04

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

-1.93

Institutional Transactions

5.09

Beta

2.03

Average Sales Estimate Current Quarter

178

Average Sales Estimate Next Quarter

165

Fair Value

53.44

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-95.7

Target Price

68.14

P/E

Forward P/E

PEG

P/S

12.57

P/B

9.27

P/Free Cash Flow

82.9

EPS

-0.52

Average EPS Est. Cur. Y

0.06

EPS Next Y. (Est.)

0.09

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-10.84

Relative Volume

0.81

Return on Equity vs Sector %

-34.4

Return on Equity vs Industry %

-18.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

◆ TXG Healthcare

$59.10

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

16/20

Pullback

17/25

Volume

4/15

Valuation

10/20

TP/AR

5/10

Options

6/10

RSI

Range 1M

17.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

13/25

Growth

9/30

Estimates

9/20

Inst/Vol

7/15

Options

9/10

EPS Yr

-79.2%

EPS NY

-7.2%

52W%

50.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -48.8% upside

Quality

6/30

Valuation

3/30

Growth

10/25

Stability

9/10

LT Trend

1/5

Upside

-48.8%

Quality

MoS

-10%

TXG — P/E HistoricalHealth Information Services

10x Genomics, Inc.

Sector: Healthcare

Industry: Medical Devices

Employees: 1178

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG

Latest News

—

Caricamento notizie per TXG…

stock quote shares TXG – 10x Genomics, Inc. Stock Price stock today

news today TXG – 10x Genomics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch TXG – 10x Genomics, Inc. yahoo finance google finance

stock history TXG – 10x Genomics, Inc. invest stock market

stock prices TXG premarket after hours

ticker TXG fair value insiders trading

TXG – 10x Genomics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: TXG

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y